June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Establishing the mitogenic potential of oncostatin M on endothelial cells: therapeutic implications for age-related macular degeneration.
Author Affiliations & Notes
  • Lorena Perez Gutierrez
    Moores Cancer Center, University of California San Diego, La Jolla, California, United States
  • Pin Li
    Moores Cancer Center, University of California San Diego, La Jolla, California, United States
  • Napoleone Ferrara
    Moores Cancer Center, University of California San Diego, La Jolla, California, United States
  • Footnotes
    Commercial Relationships   Lorena Perez Gutierrez None; Pin Li None; Napoleone Ferrara None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1306 – F0121. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lorena Perez Gutierrez, Pin Li, Napoleone Ferrara; Establishing the mitogenic potential of oncostatin M on endothelial cells: therapeutic implications for age-related macular degeneration.. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1306 – F0121.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Development of novel anti-angiogenic therapies distinct from VEGF is critical for the identification of new treatments for blindness-inducing age-related macular degeneration. Leukemia inhibitory factor (LIF), a member of the IL-6 cytokine family, has recently been identified as a potent endothelial cell (EC) mitogen in vitro and in vivo. Surprisingly, although the same results were seen in vitro for oncostatin M (OSM), another member of the IL-6 family, intravitreal (iv) injection of this cytokine decreased vascular density and inhibited laser-induced CNV in vivo. We hypothesize that LIF and OSM act through distinct mechanisms to exert their mitogenic potential on ECs.

Methods : Bovine choroidal, aortic, and retinal ECs were treated with various concentrations of LIF and OSM and key signaling mechanisms were tested by western blot and RT-qPCR. siRNA was used to knock-down the main receptors for LIF and OSM. Retinas from mice subjected to LIF and OSM iv injections were flat mounted, and neovascularization and inflammatory cell infiltration were assessed by confocal microscopy.

Results : OSM promoted proliferation of choroidal and retinal ECs through the JAK-STAT3 pathway. Conversely, OSM inhibited bovine aortic EC growth also via activation of JAK-STAT3 pathway. Interestingly, OSM, but not LIF, was able to upregulate IL-6 mRNA in choroidal and retinal ECs, as opposed to aortic ECs. Moreover, the mitogenic potential of OSM was mediated by different receptors in choroidal and aortic ECs. In vivo, as opposed to LIF, OSM inhibited neovascularization at low concentrations and was associated with an increase macrophage infiltration into the retina. However, high concentrations of OSM were able to stimulate retinal angiogenesis and were associated with reduced macrophage infiltration.

Conclusions : OSM exerts opposing responses in various EC subtypes via activation of the same signaling pathway. Additionally, OSM signals through different receptors, suggesting that different EC types have unique gene expression patterns, which determines their differential responses to the same stimulus. Moreover, our in vivo data points towards a role for OSM in the recruitment of inflammatory cells such as macrophages to the retina in a concentration-dependent manner. Overall, these data demonstrate that LIF and OSM act through distinct mechanisms in ECs.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×